TRPV1 and chronic obstructive pulmonary disease: Furthermore, continued studies have also suggested that TRPV1 inhibition may suppress inflammation and fibrosis/scarring in various pathological conditions, including toxic lung injuries, inflammation during the development of asthma and chronic obstructive pulmonary disease (COPD), cardiac and intestinal renal fibrosis, atherosclerosis, congestive heart failure, pulmonary and systemic hypertension, hemorrhagic shock, vascular remodeling, and even certain types of cancer, thereby eliciting improved wound healing outcomes [26–33].